Important Discussions
Featuring Scott Drew, DO |

Medical and Surgical Dermatologist
Dermatology Associates of Mid Ohio
Marion, OH

| Published January 03, 2024

Join Scott Drew, DO, as he shares his approach to discussing the SILIQ® (brodalumab) injection Risk Evaluation and Mitigation Strategy (REMS) Program with his patients. Dr. Drew details how he offers guidance to his adult patients being treated for moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

Dr. Drew explains the importance of discussing the patient's mental health history and contextualizes the topic of the risk of suicidal behavior, including completed suicides, which have occurred in patients treated with SILIQ in clinical trials.

See the Full Prescribing Information, including BOXED WARNING about suicidal ideation and behavior, here.


The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved